Spruce Biosciences, Inc.

Phase 3 AI-extracted

TA-ERT

MPS IIIB

Date

TBD

Phase 3 readout · Date TBD estimated

What's at stake Phase 3 trial results for TA-ERT in MPS IIIB are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 14h ago

“Data from two different analyses were presented highlighting TA-ERT as potentially the first disease-modifying treatment option for MPS IIIB.”